Read, Watch or Listen

The FDA is roiled by the resignation of George Tidmarsh, former head of the Center for Drug Evaluation and Research, after a lawsuit by Aurinia Pharmaceuticals alleged he defamed its lupus nephritis drug on LinkedIn, spurring a 20 percent stock drop, and sought revenge against board chair Kevin Tang—claims he denies. Tidmarsh had faced criticism for moving away from expert advisory meetings. Axios described staff texts showing dismay and rising attrition fears. An FDA spokesperson said he was placed on administrative leave over serious personal conduct concerns before he quit.

Prepared by Lauren Mitchell and reviewed by editorial team.